The company’s lead candidate is PTM-101, a minimally invasive, implantable treatment for pancreatic cancer providing sustained release of paclitaxel. PTM-101 is a biodegradable bilayer film ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback